Hi {{first name | there}},

A lot of longevity advice optimizes the wrong thing, much like alphabetizing the spice drawer while the smoke alarm is going off.

Whole-body MRI. Biological-age tests. CGMs. Sleep scores. Red light. Cold plunges. NAD+. Rapamycin. Peptides. A supplement drawer with the complexity of a small airport.

I am not against optimization.

I am against bad prioritization.

A good longevity audit should start with one simple question:

What is the most preventable thing most likely to shorten my life or shrink my independence, and have I actually closed that loop?

Or if you want an equation:

Priority = absolute risk x preventability x actionability x evidence quality x personalization.

Read on for how to apply the spring cleaning mindset to your own longevity.

The usual wellness checklist is defined by what performs well with the social media algorithm.

It asks whether you are tracking HRV, eating enough protein, supplementing magnesium, doing Zone 2, taking creatine, meditating, testing hormones, considering CGM, and avoiding seed oils with the seriousness of a border crossing.

While each of these things is interesting and relevant, this is not a priority system. It is more like a junk drawer full of random health objects.

A real audit starts with the risks most likely to hurt you and the steps most likely to change that.

In the U.S., heart disease and cancer remain the top causes of death, and unintentional injuries are still near the top of the list in CDC/NCHS mortality data. Globally, high systolic blood pressure, smoking, high fasting glucose, high LDL cholesterol, high BMI, alcohol, kidney dysfunction, and air pollution are among the major risk factors in the GBD 2021 risk-factor analysis.

Plus, aging biology matters. The hallmarks of aging help explain why the basics work: mitochondrial dysfunction, cellular senescence, dysregulated nutrient sensing, chronic inflammation, loss of repair capacity, and the rest of the geroscience map.

In humans, that map starts with the big things: blood pressure, ApoB and Lp(a), cancer screening, insulin resistance and visceral fat, kidney and liver signals, sleep apnea, strength and balance, and the asymmetric risks like tobacco/nicotine and alcohol. The microbiome panel can wait until you know your blood pressure.

A 34-year-old cyclist with a father who had an MI at 49 has a different first pass than a 66-year-old with falls, insomnia, hypertension, ten medications, and a glass of wine that keeps becoming three.

You don’t need a bigger dashboard.

You need the right next action.

Before you start with longevity optimization, you need to clear red flags.

A longevity audit is for prevention and risk review in people who are generally stable. Too often, the longevity field attracts those who are in a crisis and it’s very tempting to approach things in the wrong order.

Chest pain, shortness of breath out of proportion, fainting, new neurologic symptoms, a new severe headache, unexplained weight loss, blood in stool, persistent fevers, abnormal bleeding, new focal weakness, severe depression, suicidal thoughts, or another similar red flag is not fixed with a biological age reversal.

Same for alarm signs: a positive stool test, abnormal mammogram, persistently high blood pressure, rising creatinine, unexplained anemia, abnormal bleeding, or a lab your clinician asked you to repeat.

Before anything else: Is there already a warning light I am trying to ignore?

Next are the loops that are constant, measurable, and fixable.

If you buy only one home device, make it a validated upper-arm blood pressure cuff.

Not sexy. Extremely useful.

Blood pressure is common, silent, measurable, and actionable. It drives stroke, heart disease, heart failure, kidney disease, vascular brain injury, and pregnancy-related risk patterns. In a large individual participant-level meta-analysis, blood-pressure lowering reduced major cardiovascular events across a wide range of baseline pressures.

How to measure properly?

Optimal BP is <120/<80, while a home average ≥130/80 is high enough to take to a doctor.

The most common fatal surprise is often not a surprise if you check early.

It is years of blood pressure, ApoB-containing particles, glucose, inflammation, and family history adding up in the background.

The audit is not “is my cholesterol normal?” It is:

For many low- to intermediate-risk primary-prevention adults, LDL-C <100 mg/dL, non-HDL-C <130 mg/dL, and ApoB <90 mg/dL are reasonable target ranges.

ASCVD, familial hypercholesterolemia, diabetes with risk enhancers, CKD, high CAC, or very high lifetime risk usually moves the target lower: often LDL-C <70, sometimes <55, with ApoB roughly <60-70 depending on the guideline and context.

LDL-C ≥160, ApoB ≥130, or Lp(a) ≥50 mg/dL / ≥125 nmol/L is an indication to tackle this risk with the help of a doctor.

If you are getting imaging, CAC is affordable but limited to only late-stage plaque (hardened). Consider a CT cardiac angiogram with AI if you’re opting for the best screen, especially if you have any risk factors.

Do not let this collapse into just checking A1c.

Look for patterns across glucose, visceral adiposity, triglyceride-rich particles, fatty-liver risk, kidney injury, blood pressure, and sleep apnea. None of those has to look dramatic on its own to matter if multiple are looking out of range at once.

Measure it with:

Useful flags:

If prediabetes or visceral adiposity is present, “eat better” is not a plan. The Diabetes Prevention Program target was about 7% weight loss and at least 150 minutes/week of moderate activity; intensive lifestyle reduced diabetes incidence by 58% over about three years, with metformin reducing it by 31%. By the end, this part of the audit should point somewhere specific: nutrition, resistance training, weight-loss medication, alcohol or medication contributors, sleep-apnea evaluation, or kidney/liver follow-up.

Cancer screening is not “scan everything.” It is also not “wait passively until an average-risk guideline gives you permission to think.”

The audit question is: am I up to date, was every abnormal result actually closed, and does family history, genetics, breast density, smoking history, symptoms, prior findings, or personal risk move the starting line earlier?

At the very least, follow the basic guidelines: colorectal screening starting at 45 for average-risk adults; breast screening from 40 to 74 by interval and risk; and cervical screening by age and HPV/cytology strategy.

Then layer in lung screening for people who meet smoking-history criteria, prostate shared decision-making for many men 55 to 69, and skin evaluation based on changing lesions and individual risk.

Selective vascular screening follows the same logic. AAA ultrasound is a one-time screen for men 65 to 75 who have ever smoked, selective for some other risk patterns, and not a general-population scan. Intracranial aneurysm screening is not a casual add-on; it is for specific high-risk contexts, like strong family history or certain genetic diseases.

I am more proactive here than the most conservative reading of the guidelines. Multi-cancer early detection (MCED) blood tests and whole-body MRI screening are imperfect, but they are emerging and promising. For the right person, I think they can be worth considering — sometimes worth doing — if the patient understands the tradeoffs before ordering.

The informed-consent conversation matters: false positives, incidental findings, follow-up scans or biopsies, cost, anxiety, and uncertain mortality benefit are real. The test is not “can we find something?” It is: if we find something, do we have a rational follow-up plan?

Some risks are so obvious that longevity people skip them.

Tobacco and nicotine belong in asymmetric risks because the downside is huge and the intervention is clear: get combustible tobacco to zero, and treat nicotine dependence instead of moralizing it.

For people who smoke or vape, the plan is not shame. It is treatment: behavioral support, medication when appropriate, harm reduction when needed, and close follow-up. Smokeless tobacco deserves attention too.

Alcohol also belongs in this layer.

It’s true that no amount of alcohol is good for you, according to the latest studies, but it’s also true that you can enjoy a limited amount infrequently without any lasting harm.

Ask yourself:

Seat belts and helmets belong here too.

If you drive or ride in cars, seat belts matter a lot. If you bike, helmets matter. If you ski, ride motorcycles, use e-bikes, commute sleep deprived, or mix alcohol with risky activity, your audit should reflect that exposure.

The NHTSA cites seat belts as reducing fatal injury risk by about 45% in front-seat passenger cars and 60% in light trucks. A cycling helmet systematic review and meta-analysis found helmet use associated with lower odds of head injury, serious head injury, facial injury, and fatal head injury.

If you bike daily, your helmet is doing far more for your longevity than your NAD+ stack.

Falls, fractures, medication burden, vaccine avoidance, and aspirin/acetaminophen/other drug misuse also live in this layer.

A fall can shrink a life fast. For community-dwelling adults 65 and older at increased fall risk, exercise interventions have strong evidence. For everyone else, start earlier: muscle and bone are easier to build before you need them.

A sedating medication can turn a normal night into a hip-fracture story. An appropriate vaccine can prevent a bad infection from becoming a functional cliff. Aspirin is prevention that can harm when used casually, especially when bleeding risk outweighs benefit.

There are many other complicated scenarios, too many to include in one newsletter, but the essential message is: don’t die for stupid, preventable reasons.

Once you’ve reduced the obvious risks as much as you can, it’s time to build reserve: fitness, strength, sleep, nutrition, and people.

Cardiorespiratory fitness — the thing people try to approximate with VO2 max — is basically the question: how much work can your body do before it taps out? It pulls in heart, lungs, vessels, muscle, mitochondria, autonomic tone, and behavior. Messy, but clinically useful.

Large observational studies and meta-analyses keep finding the same direction: fitter people die later. One updated meta-analysis estimated about an 11% lower all-cause mortality risk per 1-MET higher fitness level. Association, not magic. Still a loud signal.

You do not need to chase a lab-grade VO2 max unless it would change your plan. Pick a repeatable measure: CPET or treadmill testing if appropriate, or mile pace, six-minute walk, stairs, a familiar hill, resting-heart-rate trend, or estimated VO2 max. The floor is the guidelines target: 150-300 minutes/week of moderate activity or 75-150 minutes/week vigorous activity, plus at least two strength days. If fitness is low, the first win is moving out of the bottom tier or adding about 1 MET.

If I could only know one “longevity lab” about someone, I would rather know how much work their body can do than how many supplements they take.

Strength is the same story.

Strength is not vanity. It is getting off the floor, carrying groceries, climbing stairs, traveling, recovering from illness, and not turning every stumble into a crisis. Grip strength predicts outcomes, but it is a proxy, not a spell. Minimum target: two resistance sessions/week hitting major muscle groups. Track one simple function: five-rep sit-to-stand, grip, loaded carry, dead hang, stairs, or single-leg balance. If falls are a concern, balance work moves from “nice” to necessary.

Train the person, not just the number.

Nutrition should be measurable too. “Eat healthy” is a non-answer. Ask questions a diet can actually answer:

Sleep belongs here, but I care less about your sleep score than the pattern. Most adults need 7-9 hours/night, or at least 7 regular hours. If you already get that and still wake unrefreshed, or if there is snoring, witnessed apneas, morning headaches, daytime sleepiness, resistant hypertension, AFib, or alcohol-fragmented sleep, do not gamify the wearable. Look for the bottleneck. Sometimes that means a sleep-apnea evaluation. Wearables can show trends. They do not fully diagnose.

Social connection is not a soft extra. Meta-analytic data link loneliness and isolation with higher mortality; clinically, isolation also means no one sees the change until it is bigger.

Audit the logistics: who would notice if something was wrong, who could you call in a crisis, who do you see without needing a special occasion, and are hearing or vision problems pushing you out of the room?

Make it concrete: one person, one recurring time, one ritual that survives a busy week.

Hormones matter.

They affect sleep, mood, bone, muscle, sexual function, fertility, cardiometabolic risk, and basic day-to-day function.

The audit is not “run every hormone lab.” It is: what symptom, risk, medication, life stage, or treatment decision makes this result useful?

Reasons to check include menstrual dysfunction, infertility, PCOS, heavy bleeding, amenorrhea, pregnancy complications, perimenopause or menopause symptoms, early or surgical menopause, testosterone-deficiency symptoms in men, thyroid symptoms, bone-risk context, and medications that can distort the signal.

Menopausal hormone therapy can be appropriate for symptoms and selected risk contexts, especially near menopause. But the trial history does not support selling it as generic chronic-disease prevention; that is what the preventive-medicine guidance is getting at.

Testosterone diagnosis requires compatible symptoms or signs plus consistently low morning testosterone, not one curiosity lab. Thyroid, vitamin D, ferritin, B12, cortisol, and sex-hormone labs are useful when symptoms, risk, medications, diet, bone health, fertility, menstrual history, or treatment decisions make them useful.

Same rule for biomarkers and wearables: a useful marker changes the next decision.

Before tracking something, ask:

Do not try to overhaul your entire life in one weekend.

Here is a better 30-day version:

Home BP average from a real log: two readings morning and evening for 3 to 7 days. Meds and supplements. Recent lipids — LDL-C, non-HDL-C, ApoB if useful, and Lp(a) once. A1c or fasting glucose by age/risk. Waist trend, triglycerides/HDL, relevant liver enzymes, creatinine/eGFR plus uACR if higher risk.

Then the non-lab loops: cancer screening dates, vaccines, tobacco, alcohol, sleep duration and apnea flags, steps or activity minutes, strength sessions and one function test, falls history, and family history.

No judgment. Just inventory.

Close what is overdue before adding novelty. Schedule screening. Follow up abnormal results. Confirm high BP properly, then choose a target and plan. Ask whether ApoB, Lp(a), CAC, uACR, DXA, genetic counseling, thyroid testing, hormone evaluation, or sleep testing would change what you do. If yes, define the result that triggers action. If no, skip the noise and wait until you’re psychologically ready.

Pick from the list you just made: validated BP tracking, the 150-minutes/week activity floor, two resistance sessions, fiber toward 25-30 g/day, a protein target, a consistent 7-9 hour sleep window, a lower-alcohol experiment, a helmet, a medication review, hearing or vision care, balance work.

Pick the two that match your risk, not the two that sound most impressive.

One question. One intervention. One metric. One decision.

Good: “If I increase fiber from 12 to 28 grams/day for 8 weeks, while keeping medications stable, what happens to LDL-C, ApoB, bowel function, satiety, and glucose response?”

Bad: “I will start 12 supplements and see if I feel different.”

Longevity is not doing everything.

It is doing the thing that changes risk, in the order that matters.

I am not against advanced testing. I am against using advanced testing to avoid the obvious. Most people do not need a more elaborate dashboard before they know their home blood pressure, ApoB, Lp(a), cancer screening status, alcohol pattern, sleep bottleneck, fitness capacity, medication risks, and family-history risks.

The top loops are not glamorous. They keep showing up because they have survived contact with real patients and actual evidence.

Close those first.

Then personalize.

Then experiment.

I put the fuller checklist and clinician-question version here: the full longevity audit guide.

The best audit leaves you with one cleaner decision, not twenty new boxes.

Stay sharp,
Hillary Lin, MD

One of my most viewed videos touches on this incredible

Watch on YouTube | Subscribe to The Longevity Show

🩺 BP meds only count if the plan survives real life. A JAMA network meta-analysis compared adverse effects and discontinuation across blood-pressure drugs and combinations. Match the drug to tolerability, simplify dosing when possible, check home readings, and follow up. A perfect prescription no one takes is still just a PDF.

Advanced CKD is a reminder that high risk does not mean “add more.” In TRACK, low-dose rivaroxaban did not reduce CV death, MI, stroke, or PAD events in advanced CKD/high CV risk, and major bleeding rose. Audit lesson: more treatment intensity is not automatically better just because baseline risk is high.

⚖️ Diabetes targets need frailty context. A large older-adult type 2 diabetes cohort found mortality and admission patterns changed with frailty and HbA1c range. No new universal target here; glucose goals should be interpreted against function, hypoglycemia risk, medications, hospitalization risk, and what the patient is actually trying to preserve.

🧬 Lp(a): measure once, then manage the whole stack. A VESALIUS-CV analysis again linked higher Lp(a) to coronary events, while related high-risk lipid-therapy analyses are still mapping what therapies do to Lp(a) itself (one, two). Useful, but not a reason to ignore the rest of the stack: ApoB/LDL, BP, metabolic risk, smoking, sleep, and family-history-based escalation still carry the plan.

🧂 Primary aldosteronism is exactly the kind of hidden loop audits should catch. In one large academic-system cohort, 43.4% of hypertensive patients met at least one screening criterion, but only 4.1% were screened. EHR-based screening may help catch eligible hypertension patterns. Less shiny than “AI health.” More useful if it leads to confirmation, treatment, and better BP.

💊 Oral GLP-1s are getting more credible, but still need caveats. In a phase 2b Nature Medicine trial, once-daily oral aleniglipron produced placebo-adjusted weight loss up to 11.3% at 36 weeks, with mostly mild-to-moderate GI events and 10.4% treatment-related discontinuation across active arms. Promising signal; not approval, hard outcomes, or a head-to-head win against current injectables.

Dry Eye Society of the Americas Conference, July 10-11, New York, NY. A clinician-focused dry eye and ocular surface meeting.

Science of Skin Summit, September 17-20, Austin, TX. Speaking on AI in dermatology and skin and hair as windows into biological age.

MVMNT 2026, September 22-23, Coronado / San Diego, CA. Speaking at Vituity / MOOV's physician-led longevity and clinical innovation summit.

Livelong Women's Health Summit NYC, September 25-26, New York, NY. A two-day summit on women's health, longevity, and agency.

A few reader-supported partners, some basic and some advanced. The audit rule still applies: use the tool when it answers a real question.

If the audit leaves you with a real clinical question, not just curiosity, start on the testing page. It includes epigenetic age testing with consultation, plus organ-specific proteomic and SystemAge assessments when they fit the clinical question. More data is only useful when it sharpens the next decision.

Have a question or topic you want covered? Reply to this email.

Was this forwarded to you? Subscribe here to get The Longevity Letter in your inbox.